001     165889
005     20240229123215.0
024 7 _ |a 10.3389/fphy.2020.564836
|2 doi
024 7 _ |a altmetric:91954824
|2 altmetric
037 _ _ |a DKFZ-2020-02458
082 _ _ |a 530
100 1 _ |a Dal Bello, Riccardo
|0 P:(DE-He78)ca98a31afd9fff038336ecfcf56f268c
|b 0
|e First author
245 _ _ |a Proposal of a chemical mechanism for mini-beam and micro-beam efficacy
260 _ _ |a Heidelberg
|c 2020
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1607426070_24459
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E041#LA:E041#
520 _ _ |a This simulation study proposes a chemical mechanism to define a surrogate to the tumor control during micro- and mini-beam radiation therapy (MBRT). The main focus is proton-MBRT (pMBRT) and the methods developed are applied also to photon-MBRT (MRT). In both cases, the classical interpretation of physical dose cannot be used to explain the observed biological effect and a change of paradigm may be required. MBRT was reported to provide tumor control with reduced side effects when compared to standard dose delivery. The underlying mechanisms leading to a differential response of the normal tissue and the tumor are still unknown. In this work, we propose a chemical mechanism to describe the efficacy of MBRT. The model was developed starting from the observation that pMBRT led to long term survival without significant side effects of rats implanted with a high-grade glioma. We distribution of a generic radiation-induced molecule or radical could be a surrogate to describe the biological effect. The specific mechanisms leading to cell damage were outside the scope of this work. The molecules and radicals were selected according to a set of properties: (i) they should be stable to allow diffusion achieving coverage of the dose-valleys, (ii) they should reach a steady state in production versus removal, (iii) they should be a product of water radiolysis, and (iv) they should have oxidizing capacity. A convolution model was developed to assess the property (i) keeping the analysis as general as possible. The tumor coverage was defined widening the interpretation of the ICRU-62 recommendations. The properties (ii) and (iii) were investigated with the TRAX-CHEM software. The property (iv) was used to exclude not relevant chemical species. The results show that hydrogen peroxide fulfills all the requirements. Moreover, the modeling of its temporal and spatial distributions demonstrate that a uniform coverage of the target by this reactive oxygen specie (ROS) can be achieved during the beam-on time. The model was compared and proven to be compatible with three independent photon micro-beam and proton mini-beam animal experiments. We conclude that hydrogen peroxide is a good candidate to describe the mini-beam and micro-beam efficacy. Further experiments are proposed to experimentally benchmark the model and to correlate the hydrogen peroxide concentration to the tumor control probability.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
700 1 _ |a Becher, Tobias
|0 P:(DE-He78)49b8eff4c466e1497028f0ad44747355
|b 1
700 1 _ |a Fuss
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Krämer, M.
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Seco, Joao
|0 P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe
|b 4
|e Last author
773 _ _ |a 10.3389/fphy.2020.564836
|0 PERI:(DE-600)2635767-7
|p 564836
|t Frontiers of physics
|v 8
|y 2020
|x 1673-3487
856 4 _ |u https://www.frontiersin.org/articles/10.3389/fphy.2020.564836/full
909 C O |o oai:inrepo02.dkfz.de:165889
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)ca98a31afd9fff038336ecfcf56f268c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)49b8eff4c466e1497028f0ad44747355
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)102624aca75cfe987c05343d5fdcf2fe
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|2 G:(DE-HGF)POF3-300
|v Imaging and radiooncology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2020-09-12
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT PHYS-BEIJING : 2018
|d 2020-09-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-09-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2020-09-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-09-12
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-09-12
920 1 _ |0 I:(DE-He78)E041-20160331
|k E041
|l E041 Medizinische Physik in der Radioonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E041-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21